Press release BoxID: 311237 (QIAGEN N.V.)
  • Hulsterweg 82
  • 5912 Venlo
  • Contact person
  • Solveigh Karola Mähler
  • +49 (2103) 29-11710

QIAGEN Added to NASDAQ-100 Index

(PresseBox) (VENLO, The Netherlands, ) QIAGEN N.V. (NASDAQ: QGEN; Frankfurt, Prime Standard: QIA) today announced that its common shares will be included in the NASDAQ-100 Index effective as of the start of trading on December 21, 2009. The NASDAQ-100 Index comprises the top 100 nonfinancial securities listed on The NASDAQ Stock Market based on market capitalization. Launched in January 1985, the NASDAQ-100 Index includes companies across major industry groups.

"The addition of our securities to the NASDAQ-100 Index reflects our strong growth, consistent performance and significant value creation", said Peer M. Schatz, CEO of QIAGEN. "We are honoured to be added to this elite set of companies". QIAGEN's common shares have been trading on The NASDAQ Stock Market since the Company's initial public offering on June 28, 1996.


QIAGEN N.V., a Netherlands holding company, is the leading global provider of sample and assay technologies. Sample technologies are used to isolate and process DNA, RNA and proteins from biological samples such as blood or tissue. Assay technologies are used to make such isolated biomolecules visible. QIAGEN has developed and markets more than 500 sample and assay products as well as automated solutions for such consumables. The company provides its products to molecular diagnostics laboratories, academic researchers, pharmaceutical and biotechnology companies, and applied testing customers for purposes such as forensics, animal or food testing and pharmaceutical process control. QIAGEN's assay technologies include one of the broadest panels of molecular diagnostic tests available worldwide. This panel includes the digeneHPV Test, which is regarded as a "gold standard" in testing for highrisk types of human papillomavirus (HPV), the primary cause of cervical cancer, as well as a broad suite of solutions for infectious disease testing and companion diagnostics. QIAGEN employs more than 3,400 people in over 30 locations worldwide. Further information about QIAGEN can be found at